Baker BROS. Advisors LP Has $68.91 Million Stock Holdings in Immunocore Holdings PLC Sponsored ADR $IMCR

Key Points

• Baker BROS. Advisors LP increased its stake in Immunocore Holdings PLC by 53.3%, purchasing 807,338 shares, bringing its total holdings to 2,322,656 shares.
• Recent analyst reports show a positive outlook for Immunocore with most giving a "buy" rating, and the stock has an average price target of $56.89.
• Immunocore's latest earnings report showed revenue of $130.65 million, outperforming expectations, while still reporting a loss per share of ($0.20).

Baker BROS. Advisors LP increased its holdings in shares of Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR - Free Report) by 53.3% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,322,656 shares of the company's stock after buying an additional 807,338 shares during the quarter. Immunocore accounts for approximately 0.8% of Baker BROS. Advisors LP's holdings, making the stock its 15th biggest position. Baker BROS. Advisors LP owned approximately 4.64% of Immunocore worth $68,913,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also modified their holdings of IMCR. Deep Track Capital LP purchased a new position in shares of Immunocore during the fourth quarter valued at $15,322,000. Tang Capital Management LLC grew its holdings in shares of Immunocore by 40.7% during the fourth quarter. Tang Capital Management LLC now owns 1,555,600 shares of the company's stock valued at $45,890,000 after buying an additional 450,000 shares in the last quarter. Point72 Asset Management L.P. purchased a new position in shares of Immunocore during the fourth quarter valued at $11,897,000. T. Rowe Price Investment Management Inc. boosted its position in Immunocore by 5.2% during the first quarter. T. Rowe Price Investment Management Inc. now owns 7,051,818 shares of the company's stock valued at $209,228,000 after purchasing an additional 351,610 shares during the last quarter. Finally, BNP Paribas Financial Markets acquired a new stake in Immunocore during the fourth quarter valued at $5,697,000. Hedge funds and other institutional investors own 84.50% of the company's stock.

Immunocore Stock Up 5.5%

Shares of NASDAQ:IMCR traded up $1.94 on Friday, reaching $37.20. The company had a trading volume of 635,305 shares, compared to its average volume of 297,189. Immunocore Holdings PLC Sponsored ADR has a twelve month low of $23.15 and a twelve month high of $39.33. The stock has a 50-day moving average price of $33.62 and a 200 day moving average price of $31.57. The stock has a market capitalization of $1.87 billion, a P/E ratio of -93.00 and a beta of 0.77. The company has a quick ratio of 5.86, a current ratio of 5.89 and a debt-to-equity ratio of 1.01.

Immunocore (NASDAQ:IMCR - Get Free Report) last announced its quarterly earnings results on Thursday, August 7th. The company reported ($0.20) earnings per share for the quarter, topping analysts' consensus estimates of ($0.21) by $0.01. Immunocore had a negative return on equity of 5.40% and a negative net margin of 5.70%.The company had revenue of $130.65 million during the quarter, compared to analysts' expectations of $122.96 million. During the same quarter in the previous year, the firm earned ($0.23) earnings per share. The business's quarterly revenue was up 30.0% compared to the same quarter last year. On average, equities analysts expect that Immunocore Holdings PLC Sponsored ADR will post -0.94 EPS for the current year.

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on the company. Jefferies Financial Group assumed coverage on Immunocore in a research report on Monday, August 25th. They set a "buy" rating and a $48.00 price objective for the company. Wall Street Zen cut Immunocore from a "buy" rating to a "hold" rating in a research report on Saturday, August 9th. HC Wainwright reissued a "buy" rating and set a $100.00 price objective on shares of Immunocore in a research report on Monday, June 2nd. Zacks Research cut Immunocore from a "strong-buy" rating to a "hold" rating in a research report on Thursday. Finally, Deutsche Bank Aktiengesellschaft assumed coverage on Immunocore in a research report on Tuesday, May 27th. They set a "buy" rating and a $65.00 price objective for the company. Seven equities research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $56.89.

Immunocore Company Profile

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.